Pharmacologic Optimization of Voriconazole

PHASE3CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

November 30, 2016

Study Completion Date

January 31, 2017

Conditions
Invasive Fungal InfectionHematological Malignancy
Interventions
DRUG

voriconazole

TDM (through level of 2-5mg/L).

DRUG

voriconazole (dosing according to the SPC)

No serum concentrations are determined

Trial Locations (1)

9713GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

University Medical Center Nijmegen

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Amsterdam UMC, location VUmc

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Meander Medical Center

OTHER

collaborator

Haga Hospital

OTHER

collaborator

Klinikum Oldenburg gGmbH

OTHER

lead

Jan-Willem C Alffenaar

OTHER

NCT00893555 - Pharmacologic Optimization of Voriconazole | Biotech Hunter | Biotech Hunter